John Steuart

CFO, Board of Directors

2019 - Current

Chairman of the Board, CFO

2018

SchoolDuels is the parent company of CSZ Network, a community building, online playground for high school sports. Fueled by the passion that comes with sports, SchoolDuels is building a place to hold the conversation, enthusiasm, and desired content for your local high school sports. It is a place to network, share, play, trade, research, highlight, and much more. Learn more at www.schoolduels.com or https://countysports.zone/

Managing Director

2016

Steuart Ventures is a private investment company of the John Steuart Family Office and Steuart Qualified Opportunity Fund. We stand behind visionary determined entrepreneurs solving big problems to shape a better future. Those who dare to fail greatly, dare to achieve spectacularly. We invest capital, time (often serving as temporary assistant managers and advisors), know how, experience, connections and no-cost fund raising assistance for current or later rounds. Our secret sauce at Steuart Ventures goes beyond simple capital investment. The team offers portfolio companies practical and real-life advice in growth strategy, scaling, talent management, financial modeling, performance management, succession, and exit planning. We have private, long-term focused, patient capital. We participate or lead in Angel, Seed, and Early funding rounds with Later round follow-on capacity. We build new companies with thoughtful and strategic consideration to create a positive impact on our greater community.

Adjunct Professor

2022 - 2023

Adjunct Professor of Finance at Johns Hopkins Carey Business School. I revel in pushing the boundaries of financial knowledge and product development both as an academic, venture capitalist, and entrepreneur. My research interests include healthcare technology, AI/ChatGT, paradigm changing start-ups, and private financial markets. I currently teach Entrepreneurial Finance at the Johns Hopkins Carey Business School. BU.233.730 Entrepreneurial Finance (Lecturer for multiple classes and semesters) BU 232.770: Cryptos & Blockchain (Guest Lecturer with Professor Jim Liew)

Advisor -- Tech Enabled Business Services

2016 - 2019

Building great businesses with the Savviest Entrepreneurs and Business Builders.

Board of Directors (NTRA), Audit Committee, Compensation Committees

2007 - 2019

Served as an active member of the Natera’s (NTRA) Board of Directors, including stints as Chairman of the Compensation Committee and Chairman of the Audit Committee. Led the Series A venture financing round of Natera together with Sequoia Capital (Roelof Botha). Engineered a successful Series B round of Natura during the high of the Great Financial Recession in 2009. Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment. Through a cfDNA technology platform approach, we've pioneered noninvasive testing in unlimited applications—each with their own potential to revolutionize care for patients.

Board of Directors & Venture Capital Investor

2012 - 2016

Led the Series C round of venture capital financing together with Sequoia Capital (Warren Hogarth). Assurex Health is a medical company that develops neuropsychiatric genomic diagnostic tests. The company was acquired by Myriad Genetics (MYGN) for $410 million in 2016. Assurex Health is a medical company that develops neuropsychiatric medicine, helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well as evidence-based medicine and clinical pharmacology.

Venture Capital Managing Director

2013 - 2015

Partnering with great entrepreneurs to build great companies. Raised Fund IV with my partners from institutional investors and led portfolio company investments. Learn more about Prolog Ventures at www.prologventures.com.

Venture Capital Managing Director & Co-Founder

2004 - 2012

Claremont Creek Ventures invests in early stage, high growth, technology and healthcare companies. You can learn more about Claremont Creek Ventures at the web site www.claremontcreek.com. John and his co-founders raised $300 million from institutional investors such as Harvard, UC Regents, Vanderbilt, U Michigan, and Verizon. John led the Series A investment in Natera (NTRA) together with Sequoia Capital. The molecular diagnostic company successfully completed an IPO in July 2015. In August 2015 Roche acquired John's portfolio company GeneWeave in a $425 million transaction. In August 2016, Myraid Genetics purchased John's portfolio company Assurex in a $410 million deal. John currently serves on the boards of Natera (NTRA) and SmartZip.

Board of Directors & Venture Capital Investor

2005 - 2007

Led first institutional round of venture capital in PropertyBridge, a fintech rent payment application. Incubated the company in our Claremont Creek offices. Pivoted the strategy to focus on very large apartment owners with focus on debit and eCheck products leading to rapid growth and an early buyout offers. PropertyBridge was acquired by MoneyGram International, Inc. on 10/1/07.